Skip to main content

Exclusive: US Retail Marijuana Sales On Pace To Rise 35% In 2019 And Near $30 Billion By 2023

Retail sales of medical and recreational cannabis in the United States are on pace to eclipse $12 billion by the end of 2019 – an increase of roughly 35% over 2018 – and could rise as high as $30 billion by 2023.

That’s according to exclusive projections from the forthcoming 2019 edition of the Marijuana Business Factbook.

Continued sales gains in recreational markets as well as the rapid development of medical marijuana programs in newly legalized states will spur much of that growth over the coming year.

In 2019, new medical markets, including Florida, Maryland, Ohio, Oklahoma and Pennsylvania, saw strong patient demand, broad lists of qualifying conditions and adequate access to dispensaries propel sales beyond initial expectations.

Although medical sales are projected to increase at the same rate as recreational sales in 2019, growth on the medical side of the industry is expected to slow significantly over the long term.

The two largest medical markets in the nation – California and Michigan – will likely see precipitous declines in MMJ sales as rec programs in both states get off the ground. The third-largest medical market – Arizona – is poised to pass adult-use legalization via a ballot initiative in 2020.

Furthermore, only a handful of states remain where medical use is not legal, and many of those – including South Dakota, Wisconsin and Wyoming – have expressed little to no interest in changing that.

As such, the potential for new medical marijuana states coming online and boosting overall sales is beginning to dry up.

On the recreational side, estimated sales in 2018 were revised up slightly from our original forecast at the beginning of 2018.

California’s massive new adult-use industry got off to a slow start, as high taxes, local licensing restrictions and a cumbersome bureaucracy made it difficult for licensed businesses to compete with the state’s entrenched black- and gray-market operators.

But by the end of 2018, the number of licensed retail stores and delivery services in California was up considerably, pushing estimated sales past the $2 billion mark.

Sales in mature markets such as Colorado, Oregon and Washington state continue to grow, although the pace of that growth has slowed. By the end of 2019, each of those states could post single-digit, year-over-year sales gains – the first time that’s happened in a recreational marijuana market.

Nationwide, however, rec sales are set for major growth in the coming years, as California and Massachusetts are expected to hit their strides by 2020 and markets such as Maine and Michigan come online.

Additionally, several state legislatures are actively considering recreational cannabis measures, including Delaware, Illinois, New Hampshire, New York, Rhode Island and Vermont.

By 2023, we project total retail marijuana sales in the United States will reach between $25 billion and $30 billion annually – more than a threefold increase from estimated annual sales in 2018.

Purchase your copy of the Annual Marijuana Business Factbook at mjbizdaily.com/factbook or call us directly at (720) 213-5992, ext 1.

Eli McVey can be reached at [email protected]

Original Article Source: https://mjbizdaily.com/exclusive-us-retail-marijuana-sales-on-pace-to-rise-35-in-2019-and-near-30-billion-by-2023/

Comments

Post a Comment

Popular posts from this blog

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...
Post a Comment
Read more

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...
Post a Comment
Read more

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned.  When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...
Post a Comment
Read more